Last updated: February 13, 2026
Overview
The drug identified with NDC 69238-2261 is Epclusa, marketed by Gilead Sciences. It is a fixed-dose combination therapy of sofosbuvir and velpatasvir indicated for the treatment of chronic hepatitis C virus (HCV) infection across all genotypes (1-6). This report examines the current market status, competitive landscape, pricing trends, and future price projections.
Market Position and Therapeutic Context
- Indications: Chronic hepatitis C, including all genotypes, in adult patients.
- Market launch: 2016.
- Treatment landscape:
- Competition from other direct-acting antivirals (DAAs) such as Harvoni (ledipasvir/sofosbuvir), Zepatier (elbasvir/grazoprevir), Mavyret (glecaprevir/pibrentasvir), and Vosevi (sofosbuvir/velpatasvir/voxilaprevir).
- Increasing generic availability in some regions; however, Epclusa retains exclusivity and market share in the U.S.
Market Size and Demand Drivers
- Prevalence: Approximately 2.4 million people in the U.S. live with HCV; worldwide estimates reach 58 million.
- Therapy adherence: High cure rates (>95%) with few adverse effects.
- Pricing: High price point initially set at $74,760 for a 12-week course in the U.S.
- Insurance impact: Reimbursement conditional on prior authorization, negotiations, and discounts.
Pricing Trends and Historical Data
| Year |
Average Wholesale Price (AWP) / Unit |
Notes |
| 2016 |
$74,760 for 12-week course |
Launch price in the U.S. |
| 2018 |
Negotiated discounts; actual paid prices lower |
PBMs and insurers negotiated substantial rebates.[1] |
| 2020 |
$54,000–$65,000 per treatment course |
Variability across providers and regions |
| 2022 |
Approx. $39,000–$45,000 per course |
Increased generic competition in some markets |
Price Projections
Key Factors Influencing Prices
- Patent expirations: Expected from 2028 in major markets.
- Generic entry: Limited currently but likely in regions like India and Europe by 2025.
- Reimbursement policies: Changes in U.S. Medicare and Medicaid utilization impact pricing strategies.
- Global market access: Differentiated by country income level; low-resource settings see significantly lower prices.
Competitive Landscape
| Drug |
Company |
Approved Since |
Market Share in U.S. |
List Price |
Notes |
| Epclusa |
Gilead Sciences |
2016 |
Leading among pan-genotypic agents |
~$74,760 |
First all-Genotype treatment, high efficacy |
| Mavyret |
AbbVie |
2017 |
Rapid growth in U.S. |
~$26,400 |
Shorter treatment duration, lower cost |
| Zepatier |
Merck |
2016 |
Moderate |
~$54,600 |
Genotype-specific, less used in current market |
| Vosevi |
Gilead Sciences |
2017 |
Niche in retreat |
~$75,000 |
Used post-failure or with resistance |
Regulatory and Policy Impact
- Patent protections sustain high prices until expiration.
- Value-based contracts and rebate agreements influence net prices.
- Global health initiatives promote generic use and price reductions in low-income countries.
Summary
- The current market price for Epclusa reflects high initial pricing driven by R&D recovery and market exclusivity.
- Competitive pressures, patent expirations, and negotiations are driving prices downward.
- Projections indicate significant price reductions over a 3-5 year horizon, especially with increased generic penetration outside the U.S.
- Pipeline innovations or policy changes could influence future pricing strategies.
Key Takeaways
- Original launch price was ~$74,760 per course; current net prices are often lower.
- Market entry of generics expected after patent expiry (around 2028 in major markets).
- Price declines due to competition, negotiations, and policies could reduce costs by over 50% in the next five years.
- Geographic disparities remain, with high-income countries paying more and emerging markets benefiting from lower prices.
- Patent protections, regional regulations, and health policies are primary determinants of future pricing trends.
FAQs
-
What is the current market price of Epclusa in the U.S.?
Estimated net prices range from $30,000 to $40,000 per course after discounts and rebates.
-
When will generic versions likely enter the market?
Patents are set to expire in key regions around 2028, with generic production potentially beginning shortly afterward.
-
How does Epclusa compete with other HCV treatments?
It offers pan-genotypic efficacy, high cure rates, and a once-daily regimen, maintaining its market share despite rising competition from other DAAs with lower prices.
-
What factors could influence future prices?
Patent status, generic entry, reimbursement policies, and innovation in therapeutic options.
-
Are there differences in pricing globally?
Yes, prices vary significantly due to market regulations, negotiations, and licensing agreements, often being substantially lower outside the U.S.
References
[1] IQVIA National Sales Perspective, 2022.
